36.12

0.91% -0.33

After Hours: 41.01 4.89 +13.54%

Veracyte Inc (VCYT)

Overview News Price History Option Chain Financials Discussions Forecast

Veracyte Inc stock is traded at $36.12, with a volume of 1.23M. It is down -0.91% in the last 24 hours and up +0.33% over the past month. Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.

Previous Close:

$36.45

Open:

$35.67

24h Volume:

1.23M

Relative Volume:

1.22

Market Cap:

$2.84B

Revenue:

$399.58M

Net Income/Loss:

$-54.04M

P/E Ratio:

-48.16

EPS:

-0.75

Net Cash Flow:

$40.13M

1W Performance:

+1.46%

1M Performance:

+0.33%

6M Performance:

+19.01%

1Y Performance:

+3.26%

1-Day Range:

$35.26

$36.96

1-Week Range:

$34.84

$36.96

52-Week Range:

$22.61

$47.32

Veracyte Inc Stock (VCYT) Company Profile

Name

Veracyte Inc

Sector

Healthcare (1135)

Industry

Diagnostics & Research (52)

Phone

(650) 243-6300

Address

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Employee

824

Twitter

@veracyte

Next Earnings Date

2025-02-24

Latest SEC Filings

VCYT's Discussions on Twitter

Compare VCYT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VCYT Veracyte Inc	36.12	2.87B	399.58M	-54.04M	40.13M	-0.75
TMO Thermo Fisher Scientific Inc	565.24	212.23B	43.74B	6.58B	6.11B	17.31
DHR Danaher Corp	213.83	151.20B	24.27B	3.50B	5.02B	4.8589
IDXX Idexx Laboratories Inc	722.12	57.84B	4.04B	985.66M	774.34M	12.01
A Agilent Technologies Inc	146.08	41.02B	6.79B	1.22B	1.09B	4.2644
IQV Iqvia Holdings Inc	210.96	36.42B	15.90B	1.28B	2.21B	7.2842

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Initiated	Canaccord Genuity	Hold
Mar-20-25	Initiated	Craig Hallum	Buy
Dec-05-24	Downgrade	Goldman	Buy → Neutral
Nov-15-24	Initiated	Wolfe Research	Outperform
Oct-16-24	Initiated	UBS	Buy
Oct-10-24	Initiated	Guggenheim	Buy
Feb-23-24	Reiterated	Needham	Buy
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform
Jan-07-22	Initiated	Stephens	Overweight
Nov-18-21	Resumed	Goldman	Buy
Jun-15-21	Initiated	Raymond James	Outperform
Feb-18-21	Resumed	Needham	Buy
Jan-28-21	Initiated	Truist	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-09-20	Initiated	Morgan Stanley	Underweight
Jul-31-19	Initiated	Lake Street	Buy
Jul-02-19	Initiated	Needham	Buy
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Janney	Buy → Neutral
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Aug-31-17	Resumed	BTIG Research	Buy
Nov-14-16	Resumed	Leerink Partners	Outperform
Dec-18-15	Initiated	Cantor Fitzgerald	Buy
Jun-11-15	Reiterated	Leerink Partners	Outperform
Nov-26-13	Initiated	William Blair	Outperform

View All

Veracyte Inc Stock (VCYT) Latest News

05:53 AM

Veracyte: Q3 Earnings Snapshot - News-Times

05:53 AM

05:25 AM

Veracyte shares soar as Q3 results beat estimates, guidance raised - Investing.com India

05:25 AM

04:59 AM

Earnings Flash (VCYT) Veracyte, Inc. Reports Q3 Revenue $131.9M, vs. FactSet Est of $125.0M - MarketScreener

04:59 AM

04:56 AM

Genomic diagnostics firm Veracyte Q3 revenue beats estimates on higher testings - MarketScreener

04:16 AM

04:05 AM

Veracyte Announces Third Quarter 2025 Financial Results - Business Wire

04:05 AM

07:15 AM

How Veracyte Inc. stock performs in interest rate cyclesJuly 2025 Recap & Expert Curated Trade Ideas - newser.com

07:15 AM

07:02 AM

Heatmap analysis for Veracyte Inc. and competitorsDividend Hike & Low Drawdown Trading Strategies - newser.com

07:02 AM

06:26 AM

Short interest data insights for Veracyte Inc.Earnings Risk Report & Verified Trade Idea Suggestions - newser.com

06:26 AM

05:45 AM

Is Veracyte Inc. a candidate for recovery playJuly 2025 Closing Moves & Low Risk Investment Opportunities - newser.com

05:45 AM

05:19 AM

Can Veracyte Inc. (12V) stock ride next bull market cycleWeekly Trade Summary & Stepwise Entry and Exit Trade Signals - newser.com

05:19 AM

03:44 AM

Chart based analysis of Veracyte Inc. trendsJuly 2025 Opening Moves & Safe Entry Zone Tips - newser.com

03:44 AM

03:17 AM

Technical analysis overview for Veracyte Inc. stockSell Signal & Free Safe Capital Growth Stock Tips - newser.com

03:17 AM

Can Veracyte Inc. stock beat market expectations this quarterTrend Reversal & Safe Capital Allocation Plans - newser.com

03:17 AM

01:35 AM

How to read the order book for Veracyte Inc.July 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com

01:35 AM

12:27 PM

Will Veracyte Inc. stock remain a Wall Street favoriteJuly 2025 News Drivers & Reliable Volume Spike Alerts - newser.com

12:27 PM

Nov 03, 2025

Veracyte (VCYT) Studies Highlight Afirma GRID's Role in Thyroid Cancer Research - GuruFocus

Nov 03, 2025

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing - Business Wire

Nov 03, 2025

Wakefield Asset Management LLLP Buys New Holdings in Veracyte, Inc. $VCYT - MarketBeat

Nov 03, 2025

What To Expect From Veracyte Inc (VCYT) Q3 2025 Earnings - Yahoo Finance

Nov 03, 2025

Can swing trading help recover from Veracyte Inc. lossesJuly 2025 Setups & Weekly Breakout Stock Alerts - newser.com

Nov 03, 2025

What to do if you’re stuck in Veracyte Inc.2025 Top Decliners & Community Verified Trade Alerts - newser.com

Nov 03, 2025